Agencies
Services
Division of Professional Regulation
Welcome to the Division of Professional Regulation (DPR)
The mission of the Illinois Department of Financial and Professional Regulation, Division of Professional Regulation is to serve, safeguard, and promote the health, safety, and welfare of the public by ensuring that licensure qualifications and standards for professional practice are properly evaluated, applied, and enforced.
The Division regulates a variety of health care and occupational professionals. Some of these professions include:
Physicians, Nurses, Pharmacies, Physical Therapists, Dentists, and Veterinarians, as well as;
Detectives, Cosmetologists, Barbers, Engineers, Accountants, Architects, and many more.
Want to see if your license is up for renewal? See our list of professions currently in renewal by going here.
IDFPR Issues Memo Regarding Medical Spa Services
In recent years, numerous medical spas (“medspas”) have opened in Illinois. A variety of non-surgical cosmetic procedures are performed in this setting, including injections of botulinum toxin (Botox), injections of weight loss medications, dermal fillers, laser hair removal, platelet rich plasma, and vitamins.
The Illinois Department of Financial and Professional Regulation, along with the Illinois Department of Public Health (IDPH), issued this memo on December 2, 2024 that outlines key responsibilities of medspas, includes information for compliance with IDFPR and IDPH regulations, and the need to make infection prevention a priority.
New Third-Party Financing Provision of the Dental Practice Act
The Dental Practice Act now requires dentists, dental employees, and dental agents to provide the following written notice to a patient or patient's guardian in at least 14-point font when discussing (except to state accepted forms of payment) or providing applications for financing extended by a third party. Learn more on our new informative webpage.
CONSUMER ALERT: Compounded Drug Products
The U.S. Food & Drug Administration (FDA) is aware of increased interest in compounded drug products containing semaglutide or tirzepatide. Compounded drug products can serve an important medical need for certain patients. However, compounded drug products (including compounded semaglutide and tirzepatide products) are not FDA-approved. They do not undergo premarket review by FDA for safety, effectiveness, or quality.
The FDA has published an informative letter that seeks to increase awareness of this safety concern.
